Funding the Next Generation
Innovation, speed and agility are key to finding effective treatments for mitochondrial disease. Your support is the beginning. Accelerating the research could lead to a cure.
Our accelerators are engaged philanthropists. Through our annual livestream-pitch event, our members have the opportunity to cast their vote for the project they feel the most passionate about, and ultimately see the difference their contribution makes.
How It Works
($50,000 in 2020)
Grant applications submitted by promising post-doctoral fellows
Applications reviewed and finalists selected by UMDF Scientific and Medical Advisory Board
3-5 finalists prepare “fast pitches” to be broadcast live at UMDF Symposium
casts a vote for the project they feel most passionate about
Prize awarded to winner
Right now… a researcher in a lab believes her theory could cure mitochondrial myopathy.
Right now… a scientist believes his innovation may bring about an end to Leigh syndrome.
Right now… people affected by mitochondrial disease need energy…and YOUR energy can help….but we need to go fast.
It could be an innovation that will find the cause of mitochondrial disease. Or, it may be the research that develops an effective treatment. Now is the time to accelerate that science from bench to bedside. Our patients and families are counting on your energy to help UMDF move faster toward a cure.
When you give $500 or more (cumulatively in a year), you unlock your accelerators benefits! No matter how you give – through a special event, to a designated fund or as a tribute to a patient – when you reach the accelerators level you join a group of engaged philanthropists. You will get a first-hand look at the promising ideas being developed in mitochondrial disease research.
In addition to the opportunity to jumpstart discovery for the next generation of mitochondrial disease researchers, our accelerators receive:
- Name recognition at the annual Symposium
- accelerators lapel pin
- accelerators social media badge
2020 accelerators Prize Winner
Kinsley Christopher Belle
Mutations in mitochondrial DNA result in an array of disease which can be found in nearly all tissue types of the human body. Furthermore, these mutations can exist in varying states of prevalence due to a rare phenomenon known as heteroplasmy. Heteroplasmy is the percentage of mutant mitochondrial DNA within a cell, tissue, or organ system. The level of heteroplasmy or the percentage of mutation directly correlates with disease and cellular dysfunction.
Our objective is to determine how internal factors, such as development and cell specification cues, as well as external stimulus, oxygen levels, energy substrates, and drug compounds influence mitochondria heteroplasmy. Our preliminary assessments suggest that cell-type development and cell division influence heteroplasmy in developing tissues, additionally our work on cell conditions, and small molecules has yielded promising preliminary results for possible therapeutics. This body of work serves as a template for discovering compounds that reduce mitochondrial heteroplasmy and thus disease burden in patients.
2019 accelerators Prize Winner
Ecole Polytechnique Federale de Lausanne (EPFL)
Dr. Gao was awarded a $50,000 prize for her project entitled Identification of Novel Compounds to Treat Rare Mitochondrial Diseases. The goal of this research project is to identify novel compounds that increase the amount of mitochondria and/or activate the identified pathway in lab-based cell models. The compounds that work best in the cell models will be subsequently tested in animal models of mitochondrial disease. Future work with top compound candidates have the potential to pave the way towards the development of novel drugs targeting rare mitochondrial diseases.
Scientists who are working fast toward a cure.
Vamsi K. Mootha, PhD
HARVARD MEDICAL SCHOOL • Boston, MA
“In 2004, I was a recipient of a $90,200 UMDF grant designed to support my efforts on using computational genomics to identify novel assembly factors for mitochondrial oxidative phosphorylation. With this support, I was able to recruit and hire a talented computational biologist, who proceeded to predict the mitochondrial proteome using a computational tool that led to the identification of several new disease genes, forming the basis for my lab’s first NIH grant.”
Anna-Kaisa Niemi MD, PhD
RADY CHILDREN’S HOSPITAL • San Diego, CA
“A UMDF Clinical Fellowship Award allowed me to focus on diagnosis and treatment of patients with confirmed or suspected mitochondrial disorders. The most impactful part of the fellowship for me was learning about the daily life of children and families affected by mitochondrial disorders. I now continue to use the knowledge and experience I gained that year in my work caring for critically ill infants with confirmed or suspected mitochondrial disorders.”
Michael J. Palladino, PhD
UNIVERSITY OF PITTSBURGH • Pittsburgh, PA
“In 2006, I received a $98,000 research grant from UMDF. This grant funded my research to further develop our Drosophila NARP/MILS model and allow our first venture into compound screening to identify specific drug therapies for mito patients. This award served as “bootstrap funding” helping me successfully apply to the NIH for support of numerous projects and helped secure more than $2.75M in NIH funding for mito research in my lab.”